amiodarone and fluconazole

amiodarone has been researched along with fluconazole in 28 studies

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (3.57)18.2507
2000's10 (35.71)29.6817
2010's16 (57.14)24.3611
2020's1 (3.57)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA1
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY2
Furuya, K; Lan, LB; Sanglard, D; Schuetz, EG; Schuetz, JD; Yasuda, K1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Gibaldi, M1
Beaudry, V; Cunningham, K; Gupta, SS; Rao, R; Rulli, S; Ton, VK1
Avorn, J; Fischer, MA; Solomon, DH; Teich, JM1
Gamarra, S; Park, S; Perlin, DS; Rao, R; Rocha, EM; Zhang, YQ1
Gamarra, S; Garcia-Effron, G; Park, S; Perlin, DS; Rao, R; Zhang, YQ1
Bruggisser, M; Franz, CC; Krähenbühl, S; Rätz Bravo, AE1
Baxter, BK; Butts, A; Chabrier-Rosello, Y; DiDone, L; Koselny, K; Krysan, DJ; Wellington, M1
Angelo, MR; Brilhante, RS; Cavalcanti, BC; da Silva, CR; de Andrade Neto, JB; de Moraes, MO; Grangeiro, TB; Lobo, MD; Macedo, DS; Magalhães, HI; Nobre Júnior, HV; Sidrim, JJ1
Andersen, SE; Buch, T1
de Abajo, FJ; Gaist, D; Martín-Pérez, M; Rodríguez, LAG1
Barcellos, VA; Frank, LA; Garcia, AWA; Guterres, SS; Kinskovski, UP; Kmetzsch, L; Marques, BM; Motta, H; Oliveira, NK; Pohlmann, AR; Reuwsaat, JCV; Schrank, A; Squizani, ED; Staats, CC; Vainstein, MH1

Reviews

2 review(s) available for amiodarone and fluconazole

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Drug interactions: part II.
    The Annals of pharmacotherapy, 1992, Volume: 26, Issue:6

    Topics: Amiodarone; Biological Availability; Dapsone; Didanosine; Drug Interactions; Fluconazole; Food; Humans; Intestinal Absorption; Ketoconazole; Pharmaceutical Preparations; Rifampin

1992

Other Studies

26 other study(ies) available for amiodarone and fluconazole

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
    Journal of medicinal chemistry, 2001, Jul-19, Volume: 44, Issue:15

    Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water

2001
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
    Journal of medicinal chemistry, 2002, Jun-20, Volume: 45, Issue:13

    Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding

2002
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:1

    Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dihydroergocryptine; Drug Interactions; Enzyme Inhibitors; Fluconazole; Humans; Mice; Mice, Knockout; Microsomes, Liver; Oxidoreductases, N-Demethylating; Recombinant Proteins; Reserpine; Swine; Tissue Distribution; Transfection; Vinblastine

2002
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
    Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5

    Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution

2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
QSAR-based permeability model for drug-like compounds.
    Bioorganic & medicinal chemistry, 2011, Apr-15, Volume: 19, Issue:8

    Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2011
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Antifungal activity of amiodarone is mediated by disruption of calcium homeostasis.
    The Journal of biological chemistry, 2003, Aug-01, Volume: 278, Issue:31

    Topics: Amiodarone; Antifungal Agents; Calcineurin; Calcium; Calcium Channels; Calcium-Binding Proteins; Calcium-Transporting ATPases; Drug Synergism; Fluconazole; Gene Deletion; Homeostasis; Miconazole; Molecular Chaperones; Mutation; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; TRPC Cation Channels

2003
Conversion from intravenous to oral medications: assessment of a computerized intervention for hospitalized patients.
    Archives of internal medicine, 2003, Nov-24, Volume: 163, Issue:21

    Topics: Administration, Oral; Amiodarone; Drug Therapy, Computer-Assisted; Fluconazole; Humans; Infusions, Intravenous; Levofloxacin; Medication Systems, Hospital; Metronidazole; Ofloxacin; Practice Patterns, Physicians'; Ranitidine; Reminder Systems

2003
Mechanism of the synergistic effect of amiodarone and fluconazole in Candida albicans.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5

    Topics: Amiodarone; Animals; Antifungal Agents; Calcium; Candida albicans; Candidiasis; Down-Regulation; Drug Resistance, Fungal; Drug Synergism; Enzyme Inhibitors; Ergosterol; Female; Fluconazole; Gene Expression Profiling; Genes, Fungal; Hyphae; Lysosomes; Mice; Mice, Inbred BALB C; Up-Regulation; Vacuoles

2010
Requirement for ergosterol in V-ATPase function underlies antifungal activity of azole drugs.
    PLoS pathogens, 2010, Jun-03, Volume: 6, Issue:6

    Topics: Amiodarone; Animals; Antifungal Agents; Candida albicans; Drug Synergism; Enzyme Inhibitors; Ergosterol; Female; Fluconazole; Mice; Mice, Inbred BALB C; Protons; Saccharomyces cerevisiae; Vacuolar Proton-Translocating ATPases; Vacuoles

2010
[Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole].
    Praxis, 2011, Mar-02, Volume: 100, Issue:5

    Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticholesteremic Agents; Antifungal Agents; Atorvastatin; Coronary Artery Bypass, Off-Pump; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Fluconazole; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Postoperative Complications; Pyrroles; Rhabdomyolysis

2011
A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis.
    Eukaryotic cell, 2013, Volume: 12, Issue:2

    Topics: Adenylate Kinase; Amiodarone; Animals; Antifungal Agents; Calmodulin; Cells, Cultured; Cryptococcosis; Cryptococcus neoformans; Drug Synergism; Fluconazole; Fungal Proteins; High-Throughput Screening Assays; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Microbial Sensitivity Tests; Patents as Topic; Phagocytes; Small Molecule Libraries; Structure-Activity Relationship; Suloctidil; Thioridazine

2013
Synergistic effects of amiodarone and fluconazole on Candida tropicalis resistant to fluconazole.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:4

    Topics: Amiodarone; Antifungal Agents; Candida tropicalis; Drug Resistance, Fungal; Drug Synergism; Fluconazole; Microbial Sensitivity Tests

2013
[Combination therapy with fluconazole and other QTc-prolonging drugs increase the QTc interval].
    Ugeskrift for laeger, 2015, Oct-05, Volume: 177, Issue:41

    Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antifungal Agents; Clarithromycin; Combined Modality Therapy; Drug Interactions; Electrocardiography; Fluconazole; Heart Rate; Humans; Long QT Syndrome; Male

2015
Population Impact of Drug Interactions with Warfarin: A Real-World Data Approach.
    Thrombosis and haemostasis, 2018, Volume: 118, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anticoagulants; Carbamazepine; Databases, Factual; Drug Interactions; Female; Fluconazole; Follow-Up Studies; Humans; International Normalized Ratio; Male; Miconazole; Middle Aged; Nystatin; Primary Health Care; Retrospective Studies; United Kingdom; Warfarin; Young Adult

2018
New nanotechnological formulation based on amiodarone-loaded lipid core nanocapsules displays anticryptococcal effect.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2021, Jul-01, Volume: 162

    Topics: Amiodarone; Animals; Antifungal Agents; Cryptococcosis; Fluconazole; Lipids; Mice; Microbial Sensitivity Tests; Nanocapsules; Nanotechnology

2021